Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring
Journal of Infectious Diseases, Volume 178, No. 5, Year 1998
Notification
URL copied to clipboard!
Description
The safety, pharmacokinetics, and antiretroviral activity of lamivudine alone and in combination with zidovudine was studied in pregnant women infected with human immunodeficiency virus type 1 (HIV-1) and their neonates. Women received the drugs orally from week 38 of pregnancy to 1 week after delivery. Neonate therapy began 12 h after delivery and continued for 1 week. Both treatment regimens were well-tolerated in women and newborns. Lamivudine and zidovudine pharmacokinetics in pregnant women were similar to those in nonpregnant adults. Lamivudine and zidovudine freely crossed the placenta and were secreted in breast milk. Neonatal lamivudine clearance was about half that in pediatric patients; zidovudine clearance was consistent with previous reports. HIV-1 RNA could be quantified in 17 of the 20 women. At the onset of labor/delivery, mean virus load had decreased by ∼1.5 log10 copies/mL in both treatment cohorts. Although not definitive for HIV-1 infection status, all neonates had HIV-1 RNA levels below the limit of quantification at birth and at ages 1 and 2 weeks. © 1998 by the Infectious Diseases Society of America. All rights reserved.
Authors & Co-Authors
Moodley, Jagdisea M.
South Africa, Durban
University of Kwazulu-natal
Switzerland, Geneva
Unaids
Netherlands, Amsterdam
Natl. Aids Therapy Evaluation Centre
United Kingdom, Brentford
Glaxosmithkline Plc.
Canada, Vancouver
British Columbia Centre for Excellence in Hiv-aids
Moodley, Dhayendre
South Africa, Durban
University of Kwazulu-natal
Switzerland, Geneva
Unaids
Netherlands, Amsterdam
Natl. Aids Therapy Evaluation Centre
United Kingdom, Brentford
Glaxosmithkline Plc.
Canada, Vancouver
British Columbia Centre for Excellence in Hiv-aids
Pillay, Kubendran
South Africa, Durban
University of Kwazulu-natal
Switzerland, Geneva
Unaids
Netherlands, Amsterdam
Natl. Aids Therapy Evaluation Centre
United Kingdom, Brentford
Glaxosmithkline Plc.
Canada, Vancouver
British Columbia Centre for Excellence in Hiv-aids
Coovadia, Hoosen Mahomed
South Africa, Durban
University of Kwazulu-natal
Switzerland, Geneva
Unaids
Netherlands, Amsterdam
Natl. Aids Therapy Evaluation Centre
United Kingdom, Brentford
Glaxosmithkline Plc.
Canada, Vancouver
British Columbia Centre for Excellence in Hiv-aids
Saba, Joseph
South Africa, Durban
University of Kwazulu-natal
Switzerland, Geneva
Unaids
Netherlands, Amsterdam
Natl. Aids Therapy Evaluation Centre
United Kingdom, Brentford
Glaxosmithkline Plc.
Canada, Vancouver
British Columbia Centre for Excellence in Hiv-aids
van Leeuwen, Remko
South Africa, Durban
University of Kwazulu-natal
Switzerland, Geneva
Unaids
Netherlands, Amsterdam
Natl. Aids Therapy Evaluation Centre
United Kingdom, Brentford
Glaxosmithkline Plc.
Canada, Vancouver
British Columbia Centre for Excellence in Hiv-aids
Goodwin, C.
South Africa, Durban
University of Kwazulu-natal
Switzerland, Geneva
Unaids
Netherlands, Amsterdam
Natl. Aids Therapy Evaluation Centre
United Kingdom, Brentford
Glaxosmithkline Plc.
Canada, Vancouver
British Columbia Centre for Excellence in Hiv-aids
Harrigan, P. Richard
South Africa, Durban
University of Kwazulu-natal
Switzerland, Geneva
Unaids
Netherlands, Amsterdam
Natl. Aids Therapy Evaluation Centre
United Kingdom, Brentford
Glaxosmithkline Plc.
Canada, Vancouver
British Columbia Centre for Excellence in Hiv-aids
Moore, Katy H.P.
South Africa, Durban
University of Kwazulu-natal
Switzerland, Geneva
Unaids
Netherlands, Amsterdam
Natl. Aids Therapy Evaluation Centre
United Kingdom, Brentford
Glaxosmithkline Plc.
Canada, Vancouver
British Columbia Centre for Excellence in Hiv-aids
Stone, C.
South Africa, Durban
University of Kwazulu-natal
Switzerland, Geneva
Unaids
Netherlands, Amsterdam
Natl. Aids Therapy Evaluation Centre
United Kingdom, Brentford
Glaxosmithkline Plc.
Canada, Vancouver
British Columbia Centre for Excellence in Hiv-aids
Plumb, R.
South Africa, Durban
University of Kwazulu-natal
Switzerland, Geneva
Unaids
Netherlands, Amsterdam
Natl. Aids Therapy Evaluation Centre
United Kingdom, Brentford
Glaxosmithkline Plc.
Canada, Vancouver
British Columbia Centre for Excellence in Hiv-aids
Johnson, Mark A.
South Africa, Durban
University of Kwazulu-natal
Switzerland, Geneva
Unaids
Netherlands, Amsterdam
Natl. Aids Therapy Evaluation Centre
United Kingdom, Brentford
Glaxosmithkline Plc.
Canada, Vancouver
British Columbia Centre for Excellence in Hiv-aids
Statistics
Citations: 204
Authors: 12
Affiliations: 5
Identifiers
Doi:
10.1086/314431
ISSN:
00221899
Research Areas
Infectious Diseases
Maternal And Child Health
Sexual And Reproductive Health
Study Design
Cohort Study
Participants Gender
Female